Skinbiotherapeutics PLC (LON:SBTX), a life science company focused on skin health, has announced that Dr Catherine O’Neill, CEO, will be presenting at an investor evening hosted by Turner Pope Investments (TPI) Ltd.
The event will be held on Monday 4th December in Mayfair, London W1 and will commence at 5pm.
To register your interest, please email info@turnerpope.com or call 0203 621 4121.
SkinBioTherapeutics is a life science company focused on skin health. The Company’s proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Catherine O’Neill and Professor Andrew McBain. SkinBioTherapeutics’ platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, protect skin models from infection and repair skin models. Proof of principle studies have shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas.